Qiagen NV Company Profile (NASDAQ:QGEN)

About Qiagen NV (NASDAQ:QGEN)

Qiagen NV logoQIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:QGEN
  • CUSIP: N7248210
  • Web: www.qiagen.com
Capitalization:
  • Market Cap: $7.43 billion
  • Outstanding Shares: 227,658,000
Average Prices:
  • 50 Day Moving Avg: $30.24
  • 200 Day Moving Avg: $29.31
  • 52 Week Range: $20.71 - $32.94
P/E:
  • Trailing P/E Ratio: 90.14
  • Foreward P/E Ratio: 23.65
  • P/E Growth: 2.12
Sales & Book Value:
  • Annual Revenue: $1.35 billion
  • Price / Sales: 5.50
  • Book Value: $10.67 per share
  • Price / Book: 3.06
Profitability:
  • EBIDTA: $411.52 million
  • Net Margins: 5.85%
  • Return on Equity: 10.01%
  • Return on Assets: 6.24%
Debt:
  • Debt-to-Equity Ratio: 0.41%
  • Current Ratio: 3.36%
  • Quick Ratio: 2.92%
Misc:
  • Average Volume: 829,200 shs.
  • Beta: 1.05
  • Short Ratio: 3.4
 

Frequently Asked Questions for Qiagen NV (NASDAQ:QGEN)

What is Qiagen NV's stock symbol?

Qiagen NV trades on the NASDAQ under the ticker symbol "QGEN."

How were Qiagen NV's earnings last quarter?

Qiagen NV (NASDAQ:QGEN) announced its earnings results on Wednesday, February, 1st. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.34 by $0.05. The company had revenue of $366.50 million for the quarter, compared to analyst estimates of $372.70 million. Qiagen NV had a return on equity of 10.01% and a net margin of 5.85%. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.31 EPS. View Qiagen NV's Earnings History.

When will Qiagen NV make its next earnings announcement?

Qiagen NV is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Qiagen NV.

What guidance has Qiagen NV issued on next quarter's earnings?

Qiagen NV updated its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $1.25 - $1.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.24. The company issued revenue guidance of $1.44 billion - $1.47 billion, compared to the consensus revenue estimate of $1.41 billion.Qiagen NV also updated its Q2 guidance to $0.27 - $0.28 EPS.

Where is Qiagen NV's stock going? Where will Qiagen NV's stock price be in 2017?

12 brokerages have issued 12 month price targets for Qiagen NV's shares. Their predictions range from $23.00 to $33.00. On average, they expect Qiagen NV's stock price to reach $28.25 in the next year. View Analyst Ratings for Qiagen NV.

Are investors shorting Qiagen NV?

Qiagen NV saw a drop in short interest during the month of April. As of April 13th, there was short interest totalling 2,476,754 shares, a drop of 11.1% from the March 31st total of 2,787,495 shares. Based on an average trading volume of 706,309 shares, the short-interest ratio is currently 3.5 days.

Who are some of Qiagen NV's key competitors?

Who owns Qiagen NV stock?

Qiagen NV's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (8.08%), BlackRock Inc. (3.47%), Baillie Gifford & Co. (3.20%), Vanguard Group Inc. (2.51%), Manning & Napier Advisors LLC (1.73%) and Johnston Asset Management LLC (1.58%). View Institutional Ownership Trends for Qiagen NV.

Who sold Qiagen NV stock? Who is selling Qiagen NV stock?

Qiagen NV's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Primecap Management Co. CA, Douglas Lane & Associates LLC, Credit Agricole S A, Swiss National Bank, Baillie Gifford & Co., Citadel Advisors LLC and Platinum Investment Management Ltd.. View Insider Buying and Selling for Qiagen NV.

Who bought Qiagen NV stock? Who is buying Qiagen NV stock?

Qiagen NV's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Legal & General Group Plc, Edmond DE Rothschild Holding S.A., Neuberger Berman Group LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, AQR Capital Management LLC and Credit Suisse AG. View Insider Buying and Selling for Qiagen NV.

How do I buy Qiagen NV stock?

Shares of Qiagen NV can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Qiagen NV stock cost?

One share of Qiagen NV stock can currently be purchased for approximately $32.64.

Analyst Ratings

Consensus Ratings for Qiagen NV (NASDAQ:QGEN) (?)
Ratings Breakdown: 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $28.25 (13.45% downside)

Analysts' Ratings History for Qiagen NV (NASDAQ:QGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017DZ Bank AGReiterated RatingNeutralLowView Rating Details
5/15/2017Barclays PLCReiterated RatingBuy$33.00LowView Rating Details
5/15/2017Commerzbank AgReiterated RatingBuyLowView Rating Details
5/4/2017Evercore ISIBoost Price TargetOutperform$30.00 -> $31.50HighView Rating Details
5/2/2017Deutsche Bank AGReiterated RatingBuyLowView Rating Details
2/3/2017Jefferies Group LLCReiterated RatingNeutral -> HoldN/AView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$27.00N/AView Rating Details
11/3/2016Bank of America CorpUpgradeUnderperform -> NeutralN/AView Rating Details
9/11/2016Morgan StanleySet Price TargetBuy$30.00N/AView Rating Details
8/1/2016HSBC Holdings plcUpgradeHold -> BuyN/AView Rating Details
8/1/2016MizuhoBoost Price TargetNeutral$22.00 -> $25.00N/AView Rating Details
7/25/2016Piper Jaffray CompaniesReiterated RatingNeutral$23.00N/AView Rating Details
3/15/2016Citigroup IncLower Price TargetNeutral$28.00 -> $25.00N/AView Rating Details
1/7/2016Cowen and CompanyBoost Price Target$24.00N/AView Rating Details
11/12/2015Stifel NicolausInitiated CoverageHoldN/AView Rating Details
10/30/2015Goldman Sachs Group IncLower Price Target$22.00 -> $21.00N/AView Rating Details
10/29/2015WedbushLower Price TargetNeutral$21.00 -> $20.00N/AView Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingNeutral$24.00 -> $25.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Qiagen NV (NASDAQ:QGEN)
Earnings by Quarter for Qiagen NV (NASDAQ:QGEN)
Earnings History by Quarter for Qiagen NV (NASDAQ:QGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/27/2017        
2/1/2017Q416$0.34$0.39$372.70 million$366.50 millionViewListenView Earnings Details
11/2/2016Q316$0.28$0.29$335.46 million$338.70 millionViewN/AView Earnings Details
7/28/2016Q216$0.23$0.24$326.73 million$334.40 millionViewN/AView Earnings Details
4/27/2016Q116$0.19$0.19$295.76 million$298.40 millionViewN/AView Earnings Details
2/2/2016Q415$0.32$0.33$354.47 million$349.00 millionViewN/AView Earnings Details
10/28/2015Q315$0.28$0.27$323.50 million$314.60 millionViewListenView Earnings Details
7/29/2015Q215$0.25$0.26$319.43 million$319.50 millionViewListenView Earnings Details
5/7/2015Q115$0.22$0.22$304.60 million$298.70 millionViewN/AView Earnings Details
1/28/2015Q414$0.30$0.25$367.82 million$360.80 millionViewN/AView Earnings Details
10/29/2014Q3$0.27$0.27$337.00 million$336.80 millionViewN/AView Earnings Details
7/29/2014Q214$0.25$0.26$330.76 million$331.20 millionViewN/AView Earnings Details
5/7/2014Q114$0.22$0.22$317.09 million$317.40 millionViewN/AView Earnings Details
1/29/2014Q413$0.34$0.36$365.52 million$362.60 millionViewN/AView Earnings Details
10/29/2013Q313$0.25$0.28$320.37 million$323.80 millionViewN/AView Earnings Details
7/30/2013Q213$0.24$0.27$311.75 million$316.40 millionViewN/AView Earnings Details
4/29/2013Q113$0.23$0.23$305.50 million$303.60 millionViewN/AView Earnings Details
1/29/2013Q412$0.31$0.34$327.80 million$346.50 millionViewN/AView Earnings Details
11/5/2012Q312$0.24$0.26$303.79 million$304.30 millionViewN/AView Earnings Details
7/24/2012$0.25$0.25ViewN/AView Earnings Details
4/25/2012$0.21$0.23ViewN/AView Earnings Details
1/31/2012$0.28$0.31ViewN/AView Earnings Details
11/2/2011$0.22$0.24ViewN/AView Earnings Details
7/25/2011$0.23$0.23ViewN/AView Earnings Details
4/27/2011$0.21$0.21ViewN/AView Earnings Details
1/31/2011$0.25$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Qiagen NV (NASDAQ:QGEN)
2017 EPS Consensus Estimate: $1.21
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.18$0.18$0.18
Q2 20171$0.29$0.29$0.29
Q3 20171$0.32$0.32$0.32
Q4 20171$0.42$0.42$0.42
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Qiagen NV (NASDAQ:QGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Qiagen NV (NASDAQ:QGEN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Qiagen NV (NASDAQ:QGEN)
Latest Headlines for Qiagen NV (NASDAQ:QGEN)
Source:
DateHeadline
prnewswire.com logoThe Sample Preparation Market Shows Strength in the Medical Field
www.prnewswire.com - May 22 at 9:28 AM
americanbankingnews.com logoDZ Bank AG Reaffirms Neutral Rating for Qiagen NV (QGEN)
www.americanbankingnews.com - May 15 at 1:20 PM
americanbankingnews.com logoQiagen NV (QGEN) Rating Reiterated by Commerzbank Ag
www.americanbankingnews.com - May 15 at 10:14 AM
americanbankingnews.com logoQiagen NV (QGEN) Expected to Post Quarterly Sales of $347.27 Million
www.americanbankingnews.com - May 13 at 9:42 AM
americanbankingnews.com logoZacks: Brokerages Expect Qiagen NV (QGEN) Will Announce Earnings of $0.29 Per Share
www.americanbankingnews.com - May 11 at 8:44 AM
finance.yahoo.com logoBlog Coverage: INC Research Holdings Acquires Privately Held inVentiv Health
finance.yahoo.com - May 11 at 8:23 AM
americanbankingnews.com logoQiagen NV's (QGEN) Buy Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - May 7 at 9:26 AM
americanbankingnews.com logoQiagen NV (QGEN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 5 at 10:43 PM
finance.yahoo.com logoEdited Transcript of QGEN earnings conference call or presentation 3-May-17 1:00pm GMT
finance.yahoo.com - May 5 at 7:39 PM
finance.yahoo.com logoQIAGEN NV's Getting It Done
finance.yahoo.com - May 4 at 7:36 PM
americanbankingnews.com logoWilliam Blair Weighs in on Qiagen NV's FY2018 Earnings (QGEN)
www.americanbankingnews.com - May 4 at 7:06 PM
streetinsider.com logoQiagen (QGEN) Partners With Maccura to Commercialize GeneReader NGS System in China - StreetInsider.com
www.streetinsider.com - May 4 at 8:30 AM
streetinsider.com logoQiagen NV (QGEN) PT Raised to $31.50 at Evercore ISI - StreetInsider.com
www.streetinsider.com - May 4 at 8:30 AM
americanbankingnews.com logoQiagen NV (QGEN) Rating Reiterated by Evercore ISI
www.americanbankingnews.com - May 4 at 7:20 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Very Likely to Impact Qiagen NV (QGEN) Stock Price
www.americanbankingnews.com - May 3 at 9:40 PM
rttnews.com logoQiagen NV Q1 Income Rises 13%
www.rttnews.com - May 3 at 7:34 PM
finance.yahoo.com logoQIAGEN (QGEN) Beats Q1 Earnings Estimates, Retains View
finance.yahoo.com - May 3 at 7:34 PM
americanbankingnews.com logoQiagen NV's (QGEN) "Buy" Rating Reaffirmed at Commerzbank Ag
www.americanbankingnews.com - May 3 at 9:04 AM
americanbankingnews.com logoQiagen NV (QGEN) Issues Q2 Earnings Guidance
www.americanbankingnews.com - May 2 at 7:22 PM
americanbankingnews.com logoQiagen NV (QGEN) Releases FY17 Earnings Guidance
www.americanbankingnews.com - May 2 at 7:22 PM
marketbeat.com logoQiagen beats Street 1Q forecasts
marketbeat.com - May 2 at 7:18 PM
finance.yahoo.com logoQIAGEN Reports Results for First Quarter 2017
finance.yahoo.com - May 2 at 5:14 PM
finance.yahoo.com logoQIAGEN Partners With Maccura to Localize and Commercialize GeneReader NGS System in China
finance.yahoo.com - May 2 at 9:54 AM
americanbankingnews.com logoDeutsche Bank AG Reiterates "Buy" Rating for Qiagen NV (QGEN)
www.americanbankingnews.com - May 2 at 7:32 AM
americanbankingnews.com logoQiagen NV (QGEN) Earning Somewhat Positive Press Coverage, Analysis Shows
www.americanbankingnews.com - April 30 at 12:25 AM
americanbankingnews.com logoQiagen NV (QGEN) Short Interest Update
www.americanbankingnews.com - April 29 at 10:10 AM
americanbankingnews.com logoQiagen NV (QGEN) Rating Lowered to C at TheStreet
www.americanbankingnews.com - April 27 at 3:54 PM
finance.yahoo.com logoQIAGEN NV – Value Analysis (NASDAQ:QGEN) : April 26, 2017
finance.yahoo.com - April 26 at 5:52 PM
americanbankingnews.com logoQiagen NV (QGEN) Earns Media Impact Rating of 0.44
www.americanbankingnews.com - April 26 at 4:24 PM
finance.yahoo.com logoQIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : April 25, 2017
finance.yahoo.com - April 25 at 10:18 AM
americanbankingnews.com logoQiagen NV (QGEN) Receives Coverage Optimism Rating of -0.12
www.americanbankingnews.com - April 23 at 3:13 PM
americanbankingnews.com logoQiagen NV (QGEN) Expected to Announce Quarterly Sales of $307.14 Million
www.americanbankingnews.com - April 22 at 9:33 AM
americanbankingnews.com logoQiagen NV (QGEN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 21 at 2:23 PM
americanbankingnews.com logo$0.21 Earnings Per Share Expected for Qiagen NV (QGEN) This Quarter
www.americanbankingnews.com - April 20 at 7:38 AM
finance.yahoo.com logoNew Research Suggests Potential for Additional Clinical Utility of QIAGEN's QuantiFERON-TB Gold Plus
finance.yahoo.com - April 12 at 6:38 PM
finance.yahoo.com logoQiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?
finance.yahoo.com - April 12 at 1:36 PM
finance.yahoo.com logoQIAGEN Releases Favorable GeneReader Results, Expands in NGS
finance.yahoo.com - April 7 at 12:09 PM
finance.yahoo.com logoQIAGEN N.V. to Report First Quarter 2017 Results
finance.yahoo.com - April 7 at 12:09 PM
finance.yahoo.com logoQIAGEN Posts 2016 Annual Report on its Website
finance.yahoo.com - April 7 at 12:09 PM
americanbankingnews.com logoQiagen NV (QGEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 5 at 1:46 PM
us.rd.yahoo.com logoQIAGEN's GeneReader NGS System Gains Further Validation in Oncology Research Applications With New Independent Performance Review Data
us.rd.yahoo.com - April 3 at 9:04 AM
us.rd.yahoo.com logoQIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer
us.rd.yahoo.com - March 31 at 7:35 PM
finance.yahoo.com logoQIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows
finance.yahoo.com - March 30 at 7:40 PM
finance.yahoo.com logoQIAGEN Launches First FDA-cleared JAK2 Test for Certain Type of Leukemia
finance.yahoo.com - March 29 at 8:13 PM
americanbankingnews.com logoQiagen NV (QGEN) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 1:49 PM
finance.yahoo.com logoQIAGEN NV Financials
finance.yahoo.com - March 9 at 7:16 PM
us.rd.yahoo.com logoNew Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
us.rd.yahoo.com - February 16 at 7:03 PM
us.rd.yahoo.com logoNew Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to Predict Active Tuberculosis Risk in Infants
us.rd.yahoo.com - February 16 at 7:03 PM
seekingalpha.com logoQIAGEN's (QGEN) CEO Peer Schatz on Q4 2016 Results - Earnings ... - Seeking Alpha
seekingalpha.com - February 3 at 8:25 PM
fool.com logoQIAGEN NV Continues Its Turnaround
www.fool.com - February 2 at 10:00 PM

Social

Chart

Qiagen NV (QGEN) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff